Editas Medicine, Inc. (EDIT): Price and Financial Metrics


Editas Medicine, Inc. (EDIT): $17.81

-0.67 (-3.63%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add EDIT to Watchlist
Sign Up

Industry: Biotech


Ranked

of 456

in industry

EDIT POWR Grades


  • Value is the dimension where EDIT ranks best; there it ranks ahead of 46.17% of US stocks.
  • The strongest trend for EDIT is in Growth, which has been heading up over the past 163 days.
  • EDIT's current lowest rank is in the Sentiment metric (where it is better than 2.53% of US stocks).

EDIT Stock Summary

  • EDIT's price/sales ratio is 52.47; that's higher than the P/S ratio of 96.13% of US stocks.
  • As for revenue growth, note that EDIT's revenue has grown -73.26% over the past 12 months; that beats the revenue growth of just 2.27% of US companies in our set.
  • In terms of volatility of its share price, EDIT is more volatile than 91.18% of stocks we're observing.
  • Stocks that are quantitatively similar to EDIT, based on their financial statements, market capitalization, and price volatility, are MORF, XBIT, CYCN, EVGN, and NKTR.
  • EDIT's SEC filings can be seen here. And to visit Editas Medicine Inc's official web site, go to www.editasmedicine.com.

EDIT Valuation Summary

  • EDIT's price/sales ratio is 53.5; this is 1307.89% higher than that of the median Healthcare stock.
  • EDIT's price/earnings ratio has moved down 17.1 over the prior 68 months.
  • EDIT's price/earnings ratio has moved down 17.1 over the prior 68 months.

Below are key valuation metrics over time for EDIT.

Stock Date P/S P/B P/E EV/EBIT
EDIT 2021-08-31 53.5 7.1 -26.0 -24.1
EDIT 2021-08-30 52.0 6.9 -25.3 -23.4
EDIT 2021-08-27 55.1 7.3 -26.8 -24.9
EDIT 2021-08-26 53.7 7.1 -26.2 -24.2
EDIT 2021-08-25 55.2 7.3 -26.9 -24.9
EDIT 2021-08-24 54.4 7.2 -26.5 -24.6

EDIT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EDIT has a Quality Grade of D, ranking ahead of 12.21% of graded US stocks.
  • EDIT's asset turnover comes in at 0.12 -- ranking 248th of 682 Pharmaceutical Products stocks.
  • SMMT, SAGE, and VSTM are the stocks whose asset turnover ratios are most correlated with EDIT.

The table below shows EDIT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.120 1 -0.458
2021-03-31 0.140 1 -0.450
2020-12-31 0.158 1 -0.468
2020-09-30 0.164 1 -0.447
2020-06-30 0.065 1 -0.704
2020-03-31 0.057 1 -0.806

EDIT Price Target

For more insight on analysts targets of EDIT, see our EDIT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $50.75 Average Broker Recommendation 1.79 (Moderate Buy)

EDIT Stock Price Chart Interactive Chart >

Price chart for EDIT

EDIT Price/Volume Stats

Current price $17.81 52-week high $73.03
Prev. close $18.48 52-week low $16.37
Day low $17.53 Volume 612,296
Day high $18.91 Avg. volume 1,924,614
50-day MA $28.37 Dividend yield N/A
200-day MA $40.54 Market Cap 1.22B

Editas Medicine, Inc. (EDIT) Company Bio


Editas Medicine Inc. operates as a genome editing company. It focuses on translating its genome editing technology into a class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a range of diseases at the genetic level. Editas Medicine Inc. was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. The company was founded in 2013 and is based in Cambridge, Massachusetts.


EDIT Latest News Stream


Event/Time News Detail
Loading, please wait...

EDIT Latest Social Stream


Loading social stream, please wait...

View Full EDIT Social Stream

Latest EDIT News From Around the Web

Below are the latest news stories about Editas Medicine Inc that investors may wish to consider to help them evaluate EDIT as an investment opportunity.

DDD Partners, LLC Buys Intel Corp, Novo Nordisk A/S, Broadcom Inc, Sells Adaptive ...

Investment company DDD Partners, LLC (Current Portfolio) buys Intel Corp, Novo Nordisk A/S, Broadcom Inc, DocuSign Inc, Atlas Corp, sells Adaptive Biotechnologies Corp, Editas Medicine Inc, Magna International Inc, Activision Blizzard Inc, Gentex Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, DDD Partners, LLC.

Yahoo | January 24, 2022

Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug

Editas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe.

Yahoo | January 19, 2022

Here is What Hedge Funds Think About Editas Medicine, Inc. (EDIT)

The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of September 30th. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]

Yahoo | January 14, 2022

What Kind Of Investors Own Most Of Editas Medicine, Inc. (NASDAQ:EDIT)?

If you want to know who really controls Editas Medicine, Inc. ( NASDAQ:EDIT ), then you'll have to look at the makeup...

Yahoo | January 14, 2022

Why Editas Medicine Stock Is Tumbling This Week

Shares of Editas Medicine (NASDAQ: EDIT) were tumbling 13% lower this week as of the market close on Thursday, based on data from S&P Global Market Intelligence. Editas Medicine CEO James Mullen specifically mentioned base editing in his comments at the J. P. Morgan conference and seemed a bit defensive.

Yahoo | January 13, 2022

Read More 'EDIT' Stories Here

EDIT Price Returns

1-mo N/A
3-mo -51.60%
6-mo -57.49%
1-year -72.80%
3-year -17.01%
5-year -1.44%
YTD -32.92%
2021 -62.13%
2020 136.78%
2019 30.15%
2018 -25.97%
2017 89.34%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8579 seconds.